



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 4, 2022

Smital Shah  
Chief Business and Financial Officer  
ProQR Therapeutics N.V.  
Zernikedreef 9  
2333 CK Leiden  
The Netherlands

**Re: ProQR Therapeutics N.V.**  
**Registration Statement on Form F-3**  
**Filed March 1, 2022**  
**File No. 333-263166**

Dear Ms. Shah:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Michael Davis at 202-551-4385 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: James Xu, Esq.